BioInform GenomeWeb News Premium Content Existing subscribers login here. New to BioInform? For a trial subscription click here.

Accelrys Posts Flat Revenues for Fiscal
Q1; Restructuring Costs Hit Bottom Line

[August 8, 2008]

By Vivien Marx

Accelrys CEO Mark Emkjer said that the company has had “a couple” of million-dollar orders in the pharmaceutical and life-sciences space. He added that similar opportunities are arising in new vertical markets for the firm, such as energy, chemicals, and consumer packaged goods.

Login | Subscribe